Coalition Fighting the DEA Ban on SR-17018 (& 7-OH): Update and How You Can Help

The DEA's announced ban on several substances, including 7-hydroxymitragynine and the pain-relieving compound SR-17018, presents significant harm-reduction concerns. As a biased agonist at the mu-opioid receptor, SR-17018 demonstrates effective pain management without the unwanted side effects or dose-escalation demands of opioids. Moves to place these substances into Schedule I limit essential research and obstruct access to promising alternatives. A coalition of researchers, advocates, and policymakers is organizing a response to contest the ban, including potential legal action to secure an emergency injunction. This move aims to prevent restrictive scheduling while allowing for a more thorough examination of the scientific data surrounding these compounds.